Leptospirosis Registry - LeptoScope

NCT ID: NCT04288674

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-04

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Leptospirosis is a worldwide zoonotic diseases caused by pathogenic Leptospira spp. Human are accidental hosts, who acquired infections after exposition to animal urine, contaminated water or soil, infected tissue. Incidence of invasive leptospirosis disease causing acute kidney injury, acute respiratory distress syndrome (ARDS), myocarditis, hepatic dysfunction, hemorrhage and multi-organ failure, is globally increasing and there have been frequent outbreak situation throughout the world. Due to increasing outbreak situations and globally chances in species distributions, a worldwide surveillance in epidemiology and species distribution is urgently needed. The objective of the Leptospirosis Registry - LeptoScope is to overcome the lack knowledge on epidemiology, clinical course, prognostic factors and molecular characteristics for invasive leptospirosis disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Leptospirosis is a worldwide zoonotic diseases caused by pathogenic Leptospira spp. Human are accidental hosts, who acquired infections after exposition to animal urine, contaminated water or soil, infected tissue. During bacteremia, Leptospira spp. may lead to invasive, deep-seated leptospirosis with infection of kidney, liver, heart and the central nervous system. Although cleaned from blood and most tissue by immune response, Leptospira spp. can persists and multiply in the tubuli of kidneys.

Incidence of invasive leptospirosis disease causing acute kidney injury, acute respiratory distress syndrome (ARDS), myocarditis, hepatic dysfunction, hemorrhage and multi-organ failure, is globally increasing and there have been frequent outbreak situation throughout the world. In Europe, invasive leptospirosis disease is less common than in the tropical and subtropical countries, however due to climate change incidence is rising, and there are worry-some trends concerning chancing species distribution and multiple outbreak situations throughout central Europe. Current treatment approaches consist of antibiotic therapies. Additionally, salvage supportive treatment approaches of critical ill patients are common in invasive leptospirosis disease requiring dialysis, hemodynamic support, mechanical ventilation or even extracorporeal membrane oxygenation (ECMO). Furthermore, invasive leptospirosis disease is associated with the development of chronic kidney disease.

Due to increasing outbreak situations and globally chances in species distributions, a worldwide surveillance in epidemiology and species distribution is urgently needed. Additionally, the examination of attributable mortality and costs analysis of invasive leptospirosis disease will need to be studied on a multinational basis and therefore LeptoScope will particularly use a matched case control design.

The objective of the Leptospirosis Registry - LeptoScope is to overcome the lack knowledge on epidemiology, clinical course, prognostic factors and molecular characteristics for invasive leptospirosis disease. Additionally, LeptoScope serves as a platform for monitoring complications of invasive leptospirosis disease and outbreak situations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leptospirosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Leptospirosis group

Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.

Retrospective data collection of demographics

Intervention Type OTHER

Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.

Retrospective data collection of underlying diseases

Intervention Type OTHER

Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.

Retrospective data collection of duration of hospitalization

Intervention Type OTHER

Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.

Control group

Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)

Retrospective data collection of demographics

Intervention Type OTHER

Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.

Retrospective data collection of underlying diseases

Intervention Type OTHER

Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.

Retrospective data collection of duration of hospitalization

Intervention Type OTHER

Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Retrospective data collection of demographics

Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.

Intervention Type OTHER

Retrospective data collection of underlying diseases

Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.

Intervention Type OTHER

Retrospective data collection of duration of hospitalization

Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cultural, serological, molecular or histological evidence of invasive leptospirosis diseases
* Clinical signs of disseminated leptospirosis disease without cultural, serological, molecular or histological evidence
* Case controls: Matching procedures for controls: Particularly, case controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital).

Exclusion Criteria

* Colonization or other non-invasive infection
* Cultural, serological, molecular or histological evidence without dissemination
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Cologne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Volker Burst

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Volker Burst, MD

Role: STUDY_CHAIR

University Hospital of Cologne

Felix Köhler, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Cologne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Cologne

Cologne, North Rhine-Westphalia, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Felix Köhler, MD

Role: CONTACT

+4922147897222

Felix Köhler, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Felix Köhler, MD

Role: primary

Felix Köhler, MD

Role: backup

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Version 1.0

Identifier Type: -

Identifier Source: org_study_id